ABIOMED Inc

ABIOMED — Q1 2023 Earnings Presentation

15 slides from ABIOMED's earnings presentation, Aug 4, 2022

  1. Slide 1: Q1 FY 2023 Earnings Call: Financial Results & Operational Highlights

    ® Recovering Hearts. Saving Lives. Q1 FY 2023 Earnings Call Financial Results & Operational Highlights 8/4/2022 Recovering Hearts. Saving Lives.

  2. Slide 2: Financial Results, Q1 FY 2023

    2 FINANCIAL RESULTS, Q1 FY 2023 Fiscal Year ends March 31 Revenue ($M) & Growth Rates Cash* ($M) $979 $1,004 $932 $270 $277 $862 $253 $261 $805 $248 Growth: Constant Currency1 +52% +18% +14% +13% +12% Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Reported +53% +18% +13% +12% +10% *Abio

  3. Slide 3: Summary Revenue and Patient Metrics, Q1 FY 2023

    3 SUMMARY REVENUE AND PATIENT METRICS, Q1 FY 2023 U.S. Revenue by Impella® Device U.S. Utilization by Indication Impella 5.0® / 5.5 (23%) Impella RP® Other (3%) (4%) Impella 2.5® Emergent (2%) (57%) Shock ® ® Protected PCI Impella CP (72%) (39%) Patient Performance Revenue Performance U.S. Hospital

  4. Slide 4: Abiomed Clinical Trials and Innovation Milestones

    4 ABIOMED CLINICAL TRIALS AND INNOVATION MILESTONES Q1 FY’23 Study Detail Patient Total Sites Status Enrollment New Indication for heart attacks without CGS. STEMI DTU Pivotal follows successful FDA Pilot study on Q1: 45 pts Q1: +2 sites Highest enrollment in a quarter; FDA RCT Study 186 out of 788*

  5. Slide 5: FY 2023 Guidance

    5 FY 2023 GUIDANCE Abiomed FY’23 Guidance Revenue $1.13B - $1.17B +13% - 17% YOY Constant Currency* +10 - 14% YOY Reported GAAP Operating Margin % 23 - 24% *Constant currency: The company defines constant currency revenue growth as the change in revenue between current and prior year periods using a

  6. Slide 6: Clinical Improvements in High-Risk PCI and Cardiogenic Shock

    6 CLINICAL IMPROVEMENTS IN HIGH-RISK PCI AND CARDIOGENIC SHOCK RECENT PUBLICATIONS FOR INVESTORS ONLY Recovering Hearts. Saving Lives.

  7. Slide 7: The PROTECT Series of Studies

    7 THE PROTECT SERIES OF STUDIES Only FDA RCT and Studies Ever Conducted for Hemodynamically Supported High-Risk PCI PROTECT Studies 1252 1134 626 630 448 223 626 504 20 225 PROTECT I PROTECT II PROTECT III PROTECT IV FDA Pilot FDA Pivotal RCT FDA Prospective Study Pivotal RCT 2006-2007 2007-2010 201

  8. Slide 8: PROTECT III Shows Improved Outcomes in Contemporary Practices

    8 PROTECT III SHOWS IMPROVED OUTCOMES IN CONTEMPORARY PRACTICES 90-Day MACCE PROTECT III p<0.0001 p=0.03 31.0% P=0.037 21.9% 15.1% N = 210 N = 215 N = 390 IABP Impella 2.5 Impella 2.5 / CP PROTECT II1 PROTECT III2 N = number of patients with 90-day follow-up PII-like MACCE: Death, Stroke, MI, Repeat

  9. Slide 9: LVEF Improvement Demonstrated in High-Risk Impella-Supported PCI Patients

    9 LVEF IMPROVEMENT DEMONSTRATED IN HIGH-RISK IMPELLA-SUPPORTED PCI PATIENTS PROTECT I PROTECT II RCT LVEF at Discharge LVEF at 30 days LVEF at 90 days LVEF at 90 days LVEF at 180 days 1 2 3 U.S. Impella Registry PROTECT I Prospective STUDY PROTECT II RCT STUDY Restore EF Prospective Study4 Roma-Vero

  10. Slide 10: LVEF, HF Symptoms, and Anginal Symptom Improvements Demonstrated

    10 LVEF, HF SYMPTOMS, AND ANGINAL SYMPTOM IMPROVEMENTS DEMONSTRATED IN IMPELLA -SUPPORTED HRPCI PATIENTS ® LVEF at 90 days Heart Failure Symptom Anginal Symptom 0% 1% 2% 45±14 97% Reduction in 76% 9% +29% Reduction in 14% CCS Angina Class 32% NYHA Class 44% III, IV III, IV 21% 40% 35±15 30% 28% 17%

  11. Slide 11: Unloading Pre-PCI Associated with Improved AMICS Outcome

    11 UNLOADING PRE-PCI ASSOCIATED WITH IMPROVED AMICS OUTCOME Survival to 30 Days IMPRESS in German-Denmark Southeastern cVAD Study Amsterdam University/ Cardiac Arrest 4 Shock Centers Denmark Unprotected LM Isala Hospital P=0.197 P=0.0039 P<0.001 P=0.004 P=0.21 80% 72% 60% 52% 47% 49% 48% 39% 23% 13%

  12. Slide 12: Meta-Analysis of Impella Pre-PCI vs Post-PCI Mortality in AMICS

    12 META-ANALYSIS OF IMPELLA PRE-PCI VS POST-PCI MORTALITY IN AMICS ® Timing of Impella placement in PCI for AMI complicated by CS: An updated meta-analysis • Short-term mortality was significantly reduced in those receiving pre-PCI vs. during/post-PCI Impella support (37.2% vs 53.6%, RR 0.7; CI 0.56

  13. Slide 13: RECOVER-IV Trial Summary

    13 RECOVER-IV TRIAL SUMMARY • Approach: Leverage STEMI-DTU trial network and OUS sites • Trial Hypothesis: Hemodynamic support with an Impella-based treatment strategy initiated prior to percutaneous coronary intervention (PCI) in patients with STEMI-CGS improves survival and functional outcomes com

  14. Slide 14: Appendix

    14 APPENDIX Recovering Hearts. Saving Lives.

  15. Slide 15: Impella Clinical Evidence Pathway - FDA Approvals to Class I Goals

    15 IMPELLA CLINICAL EVIDENCE PATHWAY- FDA APPROVALS TO CLASS I GOALS ® Established Safety & Effectiveness Identify & Validate Best Practices Class I Guidelines Goal Studies, RCTs, RWE for 510(k) & FDA Approval Physician Studies, RWE, Registries, FDA PAS Best Practice Impella Outcomes vs. Other Care

ABIOMED — Q1 2023 Earnings Presentation on 6ix